Jasper Therapeutics, a biotech company, has developed an experimental drug called briquilimab to treat chronic inducible urticaria, a skin condition. In a Phase 1/2 clinical trial, 14 out of 15 patients showed improvements after receiving the drug, with 10 out of 12 patients experiencing a complete response to treatment at a 120-mg dose. The drug was found to be safe and well-tolerated, with no serious side effects reported. Based on these positive initial results, Jasper plans to enroll more patients in the trial and test a higher dose of 180 mg to determine if it is more effective.
Source link
Jasper Therapeutics reports positive data for skin condition drug
